

10734306

FILE 'REGISTRY' ENTERED AT 17:14:52 ON 14 APR 2004

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 STRUCTURE UPLOADED
L4 2 S L3
L5 2 S L3
L6 30 S L3 SSS FULL

FILE 'CAPLUS' ENTERED AT 17:18:44 ON 14 APR 2004

=> s l6

L7 8 L6

=> s l7 not thieno?


7040 THIENO?

L8 8 L7 NOT THIENO?

=> d l1

L1 HAS NO ANSWERS

L1 STR




G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=> d l3

L3 HAS NO ANSWERS

L3 STR




G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=> d 1-8 bib abs hitstr

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:33981 CAPLUS
 DN 140:94043
 TI Preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis.
 IN Griesgraber, George W.
 PA 3M Innovative Properties Company, USA
 SO U.S., 86 pp., Cont. of U.S. Ser. No. 27,273, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6677349	B1	20040113	US 2003-425054	20030428
PRAI	US 2001-27273	B1	20011221		
OS	MARPAT 140:94043				
GI					



AB Title compds. [I; R1 = alkyl-NR3SO2XR4, alkenyl-NR3SO2XR4; X = bond, R5; R4 = (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl; R2 = H, (substituted) alkyl, alkenyl, aryl, heteroaryl, alkyl-O-alkyl, alkyl-O-alkenyl; R3 = H, alkyl; R5 = H, alkyl; R4R5 = atoms to form a 3-7 membered (substituted) heterocyclyl; n = 0-4; R = alkyl, alkoxy, halo, CF3], were prepared Thus, a stirred solution of 4-chloro-3-nitroquinoline in CH2Cl2 was treated with Et3N and 1,2-diamino-2-methylpropane to give 2-methyl-N1-(3-nitroquinolin-4-yl)propane-1,2-diamine. A solution of the latter in THF was cooled to 0° and treated with a 1 N NaOH solution of di-tert-Bu dicarbonate under rapid stirring followed by warming to ambient temperature and stirring overnight; addnl. di-tert-Bu dicarbonate was added and stirring was continued for 3 d. to give tert-Bu 1,1-dimethyl-2-[(3-nitroquinolin-4-yl)amino]ethylcarbamate. This in PhMe was treated with Pt/C and shaken under H2 for 6 h to give tert-Bu 2-(3-aminoquinolin-4-yl)-1,1-dimethylethylcarbamate. The aminoquinoline in CH2Cl2 was cooled to 0° and treated with Et3N and ethoxyacetyl chloride to give a syrup which was refluxed overnight with Et3N in EtOH to give tert-Bu 2-[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate. The imidazoquinoline in CH2Cl2 was treated with 3-chloroperoxybenzoic acid and stirred 2 h to give tert-Bu 2-[2-(ethoxymethyl)-5-oxido-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate. The latter in 1,2-dichloroethane was heated to 70° and treated with concentrated NH4OH; p-toluenesulfonyl chloride was added and the reaction mixture was heated in a sealed tube for 2 h to give tert-Bu 2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate. This was refluxed in EtOH containing HCl for 2 h to give 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine. 1-(2-Amino-2-methylpropyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine in CH2Cl2 at 0° was treated with Et3N and MeSO2Cl and the reaction was allowed to warm to ambient temperature overnight to give N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide (claimed compound). I induced interferon in an in vitro human blood cell system at lowest effective concns. of 0.0001-10 µM.

IT 642473-53-8P 642473-62-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


10734306

(Uses)

(preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis)


RN 642473-53-8 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)



RN 642473-62-9 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)




IT **642473-94-7P 642473-95-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis)


RN 642473-94-7 CAPLUS

CN Carbamic acid, [2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 642473-95-8 CAPLUS


CN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)- α,α -dimethyl- (9CI) (CA INDEX NAME)




RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:590833 CAPLUS
DN 139:149629
TI Preparation of amidoimidazo[4,5-c]quinolines as immune response modifiers
IN Coleman, Patrick L.; Crooks, Stephen L.; Griesgraber, George W.;
Lindstrom, Kyle J.; Merrill, Bryon A.; Rice, Michael J.
PA USA
SO U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. 6,451,810.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003144283	A1	20030731	US 2001-27218	20011221
	US 6451810	B1	20020917	US 2000-589580	20000607
	ZA 2001009854	A	20030228	ZA 2001-9854	20011129
	ZA 2001009857	A	20030228	ZA 2001-9857	20011129
	ZA 2001009861	A	20030228	ZA 2001-9861	20011129
	US 2004029877	A1	20040212	US 2001-27272	20011221
PRAI	US 1999-138365P	P	19990610		
	US 2000-589580	A2	20000607		
	US 2000-589216	A1	20000607		
	US 2001-166321	A1	20010615		
OS	MARPAT 139:149629				
GI					



I



II

AB Title compds. I [wherein R1 = alkyl-NR3COR4; R3 = independently H, alkyl or (un)substituted alkyl(hetero)aryl; R4 = alkyl or (un)substituted (hetero)aryl; R2 = H, alkenyl, (un)substituted alkyl or (hetero)aryl, etc.; R = independently alkyl, alkoxy, halo, CF3; n = 0-4; and their pharmaceutically acceptable salts] were prepared as immune response modifiers. For example, II was prepared by acylation of 1-(4-aminobutyl)-1H-imidazo[4,5-c]quinolin-4-amine with benzoyl chloride in pyridine. II induced interferon α and TNF α at concns. of 0.37 μ M and 10 μ M, resp., in human cells. Thus, I and their pharmaceutical compns. are useful for the treatment of a variety of conditions including viral diseases and neoplastic diseases (no data).

IT 313347-68-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

10734306

(Uses)

{immune response modifier; preparation of (amido)imidazo[4,5-c]quinolines as immune response modifiers}

RN 313347-68-1 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]hexahydro-2-oxo-, (3aS,4S,6aR)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313347-67-0

CMF C25 H33 N7 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT **570411-23-3P**, N-[2-[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]-2-ethoxyacetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

{immune response modifiers; preparation of (amido)imidazo[4,5-c]quinolines as immune response modifiers}

RN 570411-23-3 CAPLUS

CN Acetamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]-2-ethoxy- (9CI) (CA INDEX NAME)




IT 313350-40-2

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of (amido)imidazo[4,5-c]quinolines as immune response modifiers)

RN 313350-40-2 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:434369 CAPLUS

DN 139:26620

TI Topical pharmaceuticals comprising an immune response modifier

IN Skwierczynski, Raymond D.; Busch, Terri F.; Gust-Heiting, Amy L.;

Fretland, Mary T.; Scholz, Matthew T.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 123 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003045391	A1	20030605	WO 2002-US38190	20021127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GH, GM, GR, GU, HK, HN, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003199538	A1	20031023	US 2002-306019	20021127
PRAI	US 2001-340605P	P	20011129		
	US 2002-378452P	P	20020506		
OS	MARPAT 139:26620				
GI					



I

AB Pharmaceutical formulations comprise an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, and other heterocyclic fused ring derivs.; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid are useful for the treatment of dermal associated conditions. Topical

formulations containing, e.g., I are provided. In one embodiment, the topical formulations are advantageous for treatment of actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.


IT 534568-83-7 534568-84-8 534568-86-0

534568-89-3

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical pharmaceuticals comprising an immune response modifier)


RN 534568-83-7 CAPLUS

CN Ethanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 534568-84-8 CAPLUS

CN Propanamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 534568-86-0 CAPLUS

CN Thiourea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 534568-89-3 CAPLUS


CN Cyclopentanecarboxamide, N-[3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:429098 CAPLUS
DN 139:6873
TI Preparation of imidazoquinolinamines as immune response modifiers.
IN Crooks, Stephen L.; Griesgraber, George W.; Lindstrom, Kyle J.; Merrill, Bryon A.; Rice, Michael J.
PA 3M Innovative Properties Company, USA
SO U.S., 66 pp., Cont.-in-part of U.S. 6,541,485.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6573273	B1	20030603	US 2001-28255	20011221
	US 6541485	B1	20030401	US 2000-589236	20000607
	ZA 2001009854	A	20030228	ZA 2001-9854	20011129
	ZA 2001009857	A	20030228	ZA 2001-9857	20011129
	ZA 2001009861	A	20030228	ZA 2001-9861	20011129
	US 2004029877	A1	20040212	US 2001-27272	20011221
	US 2004014754	A1	20040122	US 2003-352604	20030128
	US 2004019048	A1	20040129	US 2003-370800	20030220
PRAI	US 1999-138365P	P	19990610		
	US 2000-589236	A2	20000607		
	US 2000-589216	A1	20000607		
	US 2001-166321	A1	20010615		
	US 2001-28255	A1	20011221		
OS	MARPAT 139:6873				
GI					




I


AB Title compds. [I; R1 = ANR3CYNR5XR4; A = alkylene, alkenylene; Y = O, S; X = bond, CO, SO2; R3 = H, alkyl; R4 = (substituted) aryl, heteroaryl, alkyl, etc.; R5 = H, alkyl; R4R5 = atoms to form 3-7 membered (un)substituted heterocyclic ring; R2 = H, alkyl, aryl, etc.; R = alkyl, alkoxy, halo, CF3; n = 0-4], were prepared. Thus, reaction of 4-morpholinecarbonyl chloride with 1-(4-aminobutyl)-1H-imidazo[4,5-c]quinolin-4-amine in pyridine afforded N4-[4-[4-amino-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-4-morpholinecarboxamide which induced interferon- α biosynthesis in human cells at a lowest concentration of 3.33

10734306


IT μ M.
313383-61-8P 313383-62-9P 313383-63-0P
313383-64-1P 313383-65-2P 313383-66-3P
313385-13-6P 313385-28-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of imidazoquinolinamines as immune response modifiers)
RN 313383-61-8 CAPLUS
CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-
N'-propyl- (9CI) (CA INDEX NAME)



RN 313383-62-9 CAPLUS
CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-
N'-propyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
CM 1
CRN 313383-61-8
CMF C19 H26 N6 O2




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 313383-63-0 CAPLUS
CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-
N'-phenyl- (9CI) (CA INDEX NAME)


10734306



RN 313383-64-1 CAPLUS
CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 313383-63-0
CMF C22 H24 N6 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 313383-65-2 CAPLUS
CN Thiourea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)

10734306




RN 313383-66-3 CAPLUS

CN Thiourea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-cyclohexyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313383-65-2


CMF C22 H30 N6 O S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 313385-13-6 CAPLUS

CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 313385-28-3 CAPLUS

CN Benzenesulfonamide, N-[[[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




IT 313350-40-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of imidazoquinolinamines as immune response modifiers)

RN 313350-40-2 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:360094 CAPLUS

DN 134:366874


TI Preparation of dye-labeled imidazoquinolines and analogs as immunomodulators

IN Wei, Ai-Ping; Tomai, Mark A.; Rice, Michael J.

10734306

PA 3M Innovative Properties Company, USA
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001034709	A1	20010517	WO 2000-US30366	20001103
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6376669	B1	20020423	US 2000-705072	20001102
	EP 1228147	A1	20020807	EP 2000-980282	20001103
	EP 1228147	B1	20040204		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004500347	T2	20040108	JP 2001-537411	20001103
	AT 258963	E	20040215	AT 2000-980282	20001103
	US 2002120141	A1	20020829	US 2002-78645	20020219
	US 6630588	B2	20031007		
	NO 2002001974	A	20020628	NO 2002-1974	20020425
PRAI	US 1999-163724P	P	19991105		
	US 2000-705072	A	20001102		
	WO 2000-US30366	W	20001103		
OS	MARPAT 134:366874				
GI					




AB Title compds. [I; R1 = ZR; R = dye residue; R2 = H, (un)substituted alkyl, (hetero)aryl(alkyl), etc.; R3,R4 = H, halo, alkyl, alkoxy, etc.; R3R4 = atoms to complete a ring; Z = spacer group], useful, inter alia, for determining the binding and/or receptor sites of the mols., were prepared. Thus, 3-nitro-4-quinolinol was aminated by H2N(CH2)4CHCO2CMe3 and the reduced product cyclocondensed with MeOCH2CH2COCl to give, in 3 addnl. steps, I [R1 = (CH2)4NHR, R2 = CH2CH2OMe, R3R4 = CH:CHCH:CH](II; R = H) which was amidated by fluorescein 5-isothiocyanate to give II (R = CSNHZ1R5, R5 = 6-hydroxy-3-oxo-3H-xanthen-9-yl, Z1 = 3-carboxy-1,4-phenylene). Data for biol. activity of 1 prepared I were given.

IT **340128-24-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of dye-labeled imidazoquinolines and analogs as immunomodulators)

RN 340128-24-7 CAPLUS

CN Boron, [N-[6-[[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]amino]-6-oxohexyl]-5-[(3,5-dimethyl-2H-pyrrol-2-ylidene-κN)methyl]-1H-pyrrole-2-propanamidato-κN1]difluoro-, (T-4)-(9CI) (CA INDEX NAME)




IT 339545-53-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dye-labeled imidazoquinolines and analogs as immunomodulators)

RN 339545-53-8 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:900462 CAPLUS

DN 134:56667

TI Preparation of sulfonamide and sulfamide substituted imidazoquinolines as immune response modifiers

IN Crooks, Stephen L.; Lindstrom, Kyle J.; Merrill, Bryon A.; Rice, Michael J.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 111 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076519	A1	20001221	WO 2000-US15722	20000608
PI W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 6331539 B1 20011218 US 2000-589216 20000607 BR 2000011433 A 20020305 BR 2000-11433 20000608				

EP 1198233	A1	20020424	EP 2000-938211	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003501474	T2	20030114	JP 2001-502852	20000608
EE 200100669	A	20030217	EE 2001-669	20000608
NZ 515967	A	20031031	NZ 2000-515967	20000608
US 2003130299	A1	20030710	US 2001-166321	20010615
NO 2001005502	A	20020207	NO 2001-5502	20011109
ZA 2001009854	A	20030228	ZA 2001-9854	20011129
ZA 2001009857	A	20030228	ZA 2001-9857	20011129
ZA 2001009861	A	20030228	ZA 2001-9861	20011129
HR 2001000890	A1	20030831	HR 2001-890	20011129
US 2004029877	A1	20040212	US 2001-27272	20011221
PRAI US 1999-138365P	P	19990610		
US 2000-589216	A	20000607		
WO 2000-US15722	W	20000608		
US 2001-166321	A1	20010615		
OS MARPAT 134:56667				
GI				



I



II


AB The title compds. [I; R1 = alkylNR3SO2XR4, alkenylNR3SO2XR4 (wherein X = a bond, NR5; R3 = H, alkyl; R4 = (un)substituted aryl, heteroaryl, alkyl, etc.; R5 = H, alkyl; R4 and R5 can combine to form 3-7 membered (un)substituted heterocyclic ring); R2 = H, alkyl, aryl, etc.; R = alkyl, alkoxy, halo, CF3; n = 0-4], useful as immune response modifiers, were prepared. Thus, reacting 5-dimethylamino-1-naphthalenesulfonyl chloride with 1-(4-aminobutyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine in the presence of N,N-diisopropylethylamine in CH2Cl2 afforded the naphthalenesulfonamide II which induced interferon α and TNF α biosynthesis in human cells at 0.12 μ M and 3.33 μ M, resp. The compds. I can induce the biosynthesis of various cytokines such as interferon α and TNF α (data given), and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT 313357-78-7P 313357-79-8P 313357-80-1P
313357-81-2P 313357-82-3P 313357-83-4P
313360-03-1P 313360-04-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamide and sulfamide substituted imidazoquinolines as immune response modifiers)

RN 313357-78-7 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 313357-79-8 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

10734306

CM 1

CRN 313357-78-7


CMF C16 H21 N5 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313357-80-1 CAPLUS

CN 2-Thiophenesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 313357-81-2 CAPLUS


CN 2-Thiophenesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-80-1


CMF C19 H21 N5 O3 S2

10734306




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 313357-82-3 CAPLUS

CN 1-Naphthalenesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-5-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 313357-83-4 CAPLUS

CN 1-Naphthalenesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-5-(dimethylamino)-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 313357-82-3
CMF C27 H30 N6 O3 S


10734306



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313360-03-1 CAPLUS

CN Sulfamide, N'-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 313360-04-2 CAPLUS

CN Sulfamide, N'-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N,N-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313360-03-1


CMF C17 H24 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:900461 CAPLUS
DN 134:56666
TI Preparation of urea substituted imidazoquinolines as immune response modifiers
IN Crooks, Stephen L.; Merrill, Bryon A.; Rice, Michael J.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076518	A1	20001221	WO 2000-US15656	20000608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 6541485 B1 20030401 US 2000-589236 20000607 EP 1198232 A1 20020424 EP 2000-938205 20000608 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003501473 T2 20030114 JP 2001-502851 20000608 EE 200100668 A 20030217 EE 2001-668 20000608 AU 766565 B2 20031016 AU 2000-53281 20000608 NZ 515968 A 20031031 NZ 2000-515968 20000608 NO 2001005504 A 20020207 NO 2001-5504 20011109 ZA 2001009854 A 20030228 ZA 2001-9854 20011129 ZA 2001009857 A 20030228 ZA 2001-9857 20011129 ZA 2001009861 A 20030228 ZA 2001-9861 20011129 HR 2001000889 A1 20030831 HR 2001-889 20011129 US 2004029877 A1 20040212 US 2001-27272 20011221 US 2004014754 A1 20040122 US 2003-352604 20030128 PRAI US 1999-138365P P 19990610 US 2000-589236 A 20000607 US 2000-589216 A1 20000607 WO 2000-US15656 W 20000608 US 2001-166321 A1 20010615				

10734306

OS MARPAT 134:56666
GI




AB The title compds. [I; R1 = alkylNR3CYNR5XR4, alkenylNR3CYNR5XR4 (wherein Y = O, S; X = a bond, CO, SO2; R3 = H, alkyl; R4 = (un)substituted aryl, heteroaryl, alkyl, etc.; R5 = H, alkyl; R4 and R5 can combine to form 3-7 membered (un)substituted heterocyclic ring); R2 = H, alkyl, aryl, etc.; R = alkyl, alkoxy, halo, CF3; n = 0-4], useful as immune response modifiers, were prepared. Thus, reacting 4-morpholinecarbonyl chloride with 1-(4-aminobutyl)-1H-imidazo[4,5-c]quinolin-4-amine in pyridine afforded II which induced interferon α biosynthesis in human cells at 3.33 μ M. The compds. I can induce the biosynthesis of various cytokines such as interferon α and TNF α (data given), and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT 313383-61-8P 313383-62-9P 313383-63-0P
313383-64-1P 313383-65-2P 313383-66-3P
313385-13-6P 313385-28-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urea substituted imidazoquinolines as immune response modifiers)

RN 313383-61-8 CAPLUS

CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-propyl- (9CI) (CA INDEX NAME)




RN 313383-62-9 CAPLUS

CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-propyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313383-61-8

CME C19 H26 N6 O2




10734306

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313383-63-0 CAPLUS

CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 313383-64-1 CAPLUS

CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313383-63-0


CMF C22 H24 N6 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 313383-65-2 CAPLUS

CN Thiourea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)

10734306




RN 313383-66-3 CAPLUS

CN Thiourea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-N'-cyclohexyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313383-65-2


CMF C22 H30 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313385-13-6 CAPLUS

CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-


10734306

N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 313385-28-3 CAPLUS

CN Benzenesulfonamide, N-[[[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




IT 313350-40-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of urea substituted imidazoquinolines as immune response modifiers)

RN 313350-40-2 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN


AN 2000:900448 CAPLUS

DN 134:56665


TI Preparation of amide substituted imidazoquinolines as immune response

modifiers
 IN Coleman, Patrick L.; Crooks, Stephen L.; Lindstrom, Kyle J.; Merrill,
 Bryon A.; Rice, Michael J.
 PA 3M Innovative Properties Company, USA
 SO PCT Int. Appl., 170 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000076505	A1	20001221	WO 2000-US15702	20000608
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6451810	B1	20020917	US 2000-589580	20000607
	EP 1187613	A1	20020320	EP 2000-950215	20000608
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2003501466	T2	20030114	JP 2001-502838	20000608
	EE 200100670	A	20030217	EE 2001-670	20000608
	NO 2001005503	A	20020208	NO 2001-5503	20011109
	ZA 2001009854	A	20030228	ZA 2001-9854	20011129
	ZA 2001009857	A	20030228	ZA 2001-9857	20011129
	ZA 2001009861	A	20030228	ZA 2001-9861	20011129
	HR 2001000888	A1	20030831	HR 2001-888	20011129
	US 2004029877	A1	20040212	US 2001-27272	20011221
PRAI	US 1999-138365P	P	19990610		
	US 2000-589580	A	20000607		
	US 2000-589216	A1	20000607		
	WO 2000-US15702	W	20000608		
	US 2001-166321	A1	20010615		
OS	MARPAT 134:56665				
GI					



I



II

AB The title compds. [I; R1 = alkylNR3COR4, alkenylNR3COR4 (wherein R4 = (un)substituted aryl, heteroaryl, alkyl, etc.); R2 = H, alkyl, alkenyl, etc.; R = alkyl, alkoxy, halo, CF3; n = 0-4] and their pharmaceutically acceptable salts, useful as immune response modifiers, were prepared. Thus, reacting 1-(4-aminobutyl)-1H-imidazo[4,5-c]quinolin-4-amine with benzoyl chloride in pyridine afforded the benzamide II which showed the lowest concentration of 0.37 μ M to induce interferon in human cells. The compds. I can induce the biosynthesis of various cytokines (data given for interferon α and TNF α) and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT 313347-67-0P 313347-68-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of amide substituted imidazoquinolines as immune response modifiers)


RN 313347-67-0 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-

10734306

imidazo[4,5-c]quinolin-1-yl]ethyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 313347-68-1 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]hexahydro-2-oxo-, (3aS,4S,6aR)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313347-67-0

CMF C25 H33 N7 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 313350-40-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amide substituted imidazoquinolines as immune response
modifiers)

10734306

RN 313350-40-2 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10734306

=> d his

(FILE 'HOME' ENTERED AT 15:29:15 ON 14 APR 2004)

FILE 'REGISTRY' ENTERED AT 15:29:22 ON 14 APR 2004

L1 STRUCTURE UPLOADED
L2 1 S L1
L3 15 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:32:38 ON 14 APR 2004

L4 3 S L3

FILE 'REGISTRY' ENTERED AT 15:38:48 ON 14 APR 2004

L5 STRUCTURE UPLOADED
L6 4 S L5
L7 66 S L5 SSS FULL
L8 51 S L7 NOT L3

FILE 'CAPLUS' ENTERED AT 15:40:29 ON 14 APR 2004

L9 4 S L8
SELECT L9 1 RN

FILE 'REGISTRY' ENTERED AT 16:28:16 ON 14 APR 2004

L10 337 S E1-E337
L11 12 S L10 AND ETHOXYMETHYL

=> s l11 and C17 H23 N5 O/mf

188 C17 H23 N5 O/MF


L12 1 L11 AND C17 H23 N5 O/MF

=> d scan

L12 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)-
 α,α -dimethyl- (9CI)

MF C17 H23 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d all

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 642473-95-8 REGISTRY

ED Entered STN: 28 Jan 2004

CN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)-
 α,α -dimethyl- (9CI) (CA INDEX NAME)


MF C17 H23 N5 O

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Ring System Data

Elemental Analysis EA	Elemental Sequence ES	Size of the Rings SZ	Ring System Formula RF	Ring Identifier RID	RID Occurrence Count
C3N2-C5N-C6	NCNC2-NC5-C6	5-6-6	C10N3	1819.154.1	1



Calculated Properties (CALC)

PROPERTY (CODE)	VALUE	CONDITION	NOTE
Bioconc. Factor (BCF)	1	pH 1	(1) ACD
Bioconc. Factor (BCF)	1	pH 4	(1) ACD
Bioconc. Factor (BCF)	1	pH 7	(1) ACD
Bioconc. Factor (BCF)	1	pH 8	(1) ACD
Bioconc. Factor (BCF)	9.23	pH 10	(1) ACD
Boiling Point (BP)	538.8+/-50.0 deg C	760 Torr	(1) ACD
Enthalpy of Vap. (HVP)	81.60+/-3.0 kJ/mol		(1) ACD
Flash Point (FP)	279.6+/-54.2 deg C		(1) ACD
Freely Rotatable Bonds (FRB)	7		(1) ACD
H acceptors (HAC)	6		(1) ACD
H donors (HD)	4		(1) ACD
Koc (KOC)	1	pH 1	(1) ACD
Koc (KOC)	1	pH 4	(1) ACD
Koc (KOC)	1	pH 7	(1) ACD
Koc (KOC)	2.54	pH 8	(1) ACD
Koc (KOC)	160	pH 10	(1) ACD
logD (LOGD)	-3.29	pH 1	(1) ACD
logD (LOGD)	-3.29	pH 4	(1) ACD
logD (LOGD)	-1.98	pH 7	(1) ACD
logD (LOGD)	-0.19	pH 8	(1) ACD
logD (LOGD)	1.60	pH 10	(1) ACD
logP (LOGP)	1.707+/-1.125		(1) ACD
Molar Solubility (SLB.MOL)	>=1 mol/L	pH 1	(1) ACD
Molar Solubility (SLB.MOL)	>=1 mol/L	pH 4	(1) ACD
Molar Solubility (SLB.MOL)	>=1 mol/L	pH 7	(1) ACD
Molar Solubility (SLB.MOL)	>=0.01 - <0.1 mol/L	pH 8	(1) ACD
Molar Solubility (SLB.MOL)	<0.01 mol/L	pH 10	(1) ACD
Molecular Weight (MW)	313.40		(1) ACD
pKa (PKA)	9.15+/-0.50	Most Basic	(1) ACD
Vapor Pressure (VP)	1.12E-11 Torr	25 deg C	(1) ACD

(1) Calculated using Advanced Chemistry Development (ACD/Labs) Software
Solaris V4.76 ((C) 1994-2004 ACD/Labs)

See HELP PROPERTIES for information about property data sources in REGISTRY.

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 140:94043 CA
 TI Preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis.
 IN Griesgraber, George W.
 PA 3M Innovative Properties Company, USA
 SO U.S., 86 pp., Cont. of U.S. Ser. No. 27,273, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K031-4745
 ICS A61K031-541; C07D471-04; C07D417-14; A61P037-02

10734306


NCL 514293000

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6677349	B1	20040113	US 2003-425054	20030428
PRAI	US 2001-27273		20011221		
GI					



AB Title compds. [I; R1 = alkyl-NR3SO2XR4, alkenyl-NR3SO2XR4; X = bond, R5; R4 = (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl; R2 = H, (substituted) alkyl, alkenyl, aryl, heteroaryl, alkyl-O-alkyl, alkyl-O-alkenyl; R3 = H, alkyl; R5 = H, alkyl; R4R5 = atoms to form a 3-7 membered (substituted) heterocyclyl; n = 0-4; R = alkyl, alkoxy, halo, CF3], were prepared. Thus, a stirred solution of 4-chloro-3-nitroquinoline in CH2Cl2 was treated with Et3N and 1,2-diamino-2-methylpropane to give 2-methyl-N1-(3-nitroquinolin-4-yl)propane-1,2-diamine. A solution of the latter in THF was cooled to 0° and treated with a 1 N NaOH solution of di-tert-Bu dicarbonate under rapid stirring followed by warming to ambient temperature and stirring overnight; addnl. di-tert-Bu dicarbonate was added and stirring was continued for 3 d. to give tert-Bu 1,1-dimethyl-2-[(3-nitroquinolin-4-yl)amino]ethylcarbamate. This in PhMe was treated with Pt/C and shaken under H2 for 6 h to give tert-Bu 2-(3-aminoquinolin-4-yl)-1,1-dimethylethylcarbamate. The aminoquinoline in CH2Cl2 was cooled to 0° and treated with Et3N and ethoxyacetyl chloride to give a syrup which was refluxed overnight with Et3N in EtOH to give tert-Bu 2-[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate. The imidazoquinoline in CH2Cl2 was treated with 3-chloroperoxybenzoic acid and stirred 2 h to give tert-Bu 2-[2-(ethoxymethyl)-5-oxido-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate. The latter in 1,2-dichloroethane was heated to 70° and treated with concentrated NH4OH; p-toluenesulfonyl chloride was added and the reaction mixture was heated in a sealed tube for 2 h to give tert-Bu 2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate. This was refluxed in EtOH containing HCl for 2 h to give 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine. 1-(2-Amino-2-methylpropyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine in CH2Cl2 at 0° was treated with Et3N and MeSO2Cl and the reaction was allowed to warm to ambient temperature overnight to give N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide (claimed compound). I induced interferon in an in vitro human blood cell system at lowest effective concns. of 0.0001-10 µM.

ST imidazoquinolinesulfonamide prepn cytokine biosynthesis inhibitor; interferon tumor necrosis factor induction imidazoquinolinesulfonamide prepn

IT Cytokines
Interferons
Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inducers; preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis)

IT Drug delivery systems
Human

(preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis)

IT	313355-83-8P	313355-85-0P	313355-87-2P	313355-89-4P	313355-90-7P
	313355-91-8P	313355-96-3P	313355-97-4P	313355-98-5P	313355-99-6P
	313356-00-2P	313356-01-3P	313356-03-5P	313356-05-7P	313356-07-9P
	313356-09-1P	313356-11-5P	313356-13-7P	313356-14-8P	313356-15-9P
	313356-17-1P	313356-19-3P	313356-21-7P	313356-23-9P	313356-25-1P
	313356-27-3P	313356-29-5P	313356-31-9P	313356-33-1P	313356-35-3P
	313356-36-4P	313356-37-5P	313356-39-7P	313356-40-0P	313356-42-2P
	313356-44-4P	313356-45-5P	313356-46-6P	313356-47-7P	313356-49-9P

313356-51-3P	313356-53-5P	313356-54-6P	313356-56-8P	313356-58-0P
313356-60-4P	313356-62-6P	313356-63-7P	313356-65-9P	313356-67-1P
313356-69-3P	313356-71-7P	313356-72-8P	313356-74-0P	313356-76-2P
313356-78-4P	313356-80-8P	313356-82-0P	313356-84-2P	313356-86-4P
313356-88-6P	313356-90-0P	313356-92-2P	313356-94-4P	313356-96-6P
313356-98-8P	313357-00-5P	313357-02-7P	313357-04-9P	313357-06-1P
313357-09-4P	313357-11-8P	313357-13-0P	313357-15-2P	313357-17-4P
313357-19-6P	313357-21-0P	313357-23-2P	313357-25-4P	313357-27-6P
313357-29-8P	313357-30-1P	313357-31-2P	313357-33-4P	313357-35-6P
313357-37-8P	313357-39-0P	313357-40-3P	313357-41-4P	313357-43-6P
313357-45-8P	313357-47-0P	313357-49-2P	313357-51-6P	313357-53-8P
313357-55-0P	313357-57-2P	313357-59-4P	313357-61-8P	313357-63-0P
313357-65-2P	313357-67-4P	313357-69-6P	313357-71-0P	313357-73-2P
313357-75-4P	313357-77-6P	313357-84-5P	313357-85-6P	313357-88-9P
313357-90-3P	313357-95-8P	313357-97-0P	313357-99-2P	313358-02-0P
313358-04-2P	313358-07-5P	313358-09-7P	313358-11-1P	313358-13-3P
313358-15-5P	313358-17-7P	313358-19-9P	313358-21-3P	313358-24-6P
313358-27-9P	313358-30-4P	313358-33-7P	313358-36-0P	313358-39-3P
313358-42-8P	313358-45-1P	313358-47-3P	313358-49-5P	313358-51-9P
313358-53-1P	313358-55-3P	313358-57-5P	313358-60-0P	313358-62-2P
313358-64-4P	313358-67-7P	313358-70-2P	313358-72-4P	313358-76-8P
313358-78-0P	313358-80-4P	313358-82-6P	313358-84-8P	313358-86-0P
313358-88-2P	313358-90-6P	313358-92-8P	313358-93-9P	313358-94-0P
313358-96-2P	313358-98-4P	313359-00-1P	313359-02-3P	313359-04-5P
313359-06-7P	313359-08-9P	313359-10-3P	313359-12-5P	313359-14-7P
313359-16-9P	313359-18-1P	313359-20-5P	313359-22-7P	313359-24-9P
313359-26-1P	313359-28-3P	313359-30-7P	313359-32-9P	313359-34-1P
313359-36-3P	313359-38-5P	313359-40-9P	313359-42-1P	313359-44-3P
313359-46-5P	313359-48-7P	313359-50-1P	313359-52-3P	313359-54-5P
313359-56-7P	313359-58-9P	313359-60-3P	313359-62-5P	313359-64-7P
313359-68-1P	313359-70-5P	313359-72-7P	313359-74-9P	313359-78-3P
313359-79-4P	313359-81-8P	313359-83-0P	313359-85-2P	313359-87-4P
313359-89-6P	313359-91-0P	313359-93-2P	313359-95-4P	313359-97-6P
313360-01-9P	313360-06-4P	313360-08-6P	313360-10-0P	313360-12-2P
313360-14-4P	313360-16-6P	313360-18-8P	313360-20-2P	313360-22-4P
313360-24-6P	313360-26-8P	313360-32-6P	313360-33-7P	532959-63-0P
534568-90-6P	642473-06-1P	642473-08-3P	642473-10-7P	642473-12-9P
642473-14-1P	642473-16-3P	642473-18-5P	642473-21-0P	642473-23-2P
642473-28-7P	642473-29-8P	642473-30-1P	642473-31-2P	642473-33-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis)

IT	642473-36-7P	642473-39-0P	642473-40-3P	642473-41-4P	642473-42-5P
	642473-43-6P	642473-44-7P	642473-45-8P	642473-46-9P	642473-47-0P
	642473-48-1P	642473-49-2P	642473-50-5P	642473-51-6P	642473-52-7P
	642473-53-8P	642473-54-9P	642473-55-0P	642473-56-1P	642473-57-2P
	642473-58-3P	642473-59-4P	642473-60-7P	642473-61-8P	642473-62-9P
	642473-63-0P	642473-65-2P			

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis)

IT	642473-24-3	642473-26-5
----	-------------	-------------

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis)

IT	98-09-9, Benzenesulfonyl chloride	98-74-8, 4-Nitrobenzenesulfonyl chloride	121-51-7, 3-Nitrobenzenesulfonyl chloride	124-63-0, Methanesulfonyl chloride	349-88-2, 4-Fluorobenzenesulfonyl chloride	358-23-6, Trifluoromethanesulfonic anhydride	594-44-5, Ethanesulfonyl chloride	605-65-2, 5-Dimethylamino-1-naphthalenesulfonyl chloride	811-93-8, 1,2-Diamino-2-methylpropane	1633-82-5, 3-Chloropropylsulfonyl chloride	1939-99-7, α -Toluenesulfonyl chloride	2386-60-9, 1-Butanesulfonyl chloride	7143-01-3, Methanesulfonic anhydride	13360-57-1, Dimethylsulfamoyl chloride	14077-58-8, Ethoxyacetyl chloride	16629-19-9, 2-Thiophenesulfonyl chloride	39061-97-7, 4-Chloro-3-nitroquinoline	105627-79-0, Isoquinoline-5-sulfonyl chloride	hydrochloride	195711-99-0	210303-90-5	210304-10-2	313350-30-0	313350-31-1	313350-39-9	313350-42-4	313350-46-8	570410-94-5	570410-96-7	570410-98-9	570411-01-7	570411-03-9	570411-07-3	642473-97-0	642473-98-1	642473-99-2	642474-00-8	642474-01-9	642474-02-0	642474-03-1	642474-04-2	642474-05-3
----	-----------------------------------	--	---	------------------------------------	--	--	-----------------------------------	--	---------------------------------------	--	---	--------------------------------------	--------------------------------------	--	-----------------------------------	--	---------------------------------------	---	---------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of imidazoquinolinesulfonamides as inducers of cytokine

biosynthesis)

IT	313350-23-1P	313350-24-2P	313350-25-3P	313350-26-4P	313350-27-5P
	313360-34-8P	313360-35-9P	313360-36-0P	570411-24-4P	642473-73-2P
	642473-74-3P	642473-75-4P	642473-76-5P	642473-77-6P	642473-78-7P
	642473-79-8P	642473-80-1P	642473-81-2P	642473-82-3P	642473-83-4P
	642473-84-5P	642473-85-6P	642473-86-7P	642473-87-8P	642473-88-9P
	642473-89-0P	642473-90-3P	642473-91-4P	642473-92-5P	642473-93-6P
	642473-94-7P	642473-95-8P			

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis)

RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD

- (1) Andre; US 4988815 A 1991 CAPLUS
- (2) Anon; EP 0394026 1990 CAPLUS
- (3) Anon; JP 09-208584 1997 CAPLUS
- (4) Anon; JP 09-255926 1999
- (5) Anon; JP 11-222432 1999 CAPLUS
- (6) Anon; WO 0047719 2000 CAPLUS
- (7) Anon; WO 0076518 2000 CAPLUS
- (8) Anon; JP 2000247884 2000 CAPLUS
- (9) Anon; WO 0174343 2001 CAPLUS
- (10) Anon; EP 1104764 2001 CAPLUS
- (11) Anon; WO 02102377 2002 CAPLUS
- (12) Anon; WO 0236592 2002 CAPLUS
- (13) Anon; WO 0246188 2002 CAPLUS
- (14) Anon; WO 0246189 2002 CAPLUS
- (15) Anon; WO 0246190 2002 CAPLUS
- (16) Anon; WO 0246191 2002 CAPLUS
- (17) Anon; WO 0246192 2002 CAPLUS
- (18) Anon; WO 0246193 2002 CAPLUS
- (19) Anon; WO 0246749 2002 CAPLUS
- (20) Anon; WO 03020889 2003 CAPLUS
- (21) Bachman; J Org Chem 1950, V15, P1278 CAPLUS
- (22) Baranov; 1976 CAPLUS
- (23) Beaurline; US 5939090 A 1999
- (24) Berenyi; J Heterocyclic Chem 1981, V18, P1537 CAPLUS
- (25) Brennan; Biotechniques 1983, Jun/Jul, P78
- (26) Chollet; Pharmaceutical Development and Technology 1999, V4(1), P35 CAPLUS
- (27) Coleman; US 6451810 B1 2002 CAPLUS
- (28) Crooks; US 6331539 B1 2001 CAPLUS
- (29) Crooks; US 6541485 B1 2003 CAPLUS
- (30) Dellaria; US 6525064 B1 2003 CAPLUS
- (31) Dellaria; US 6545016 B1 2003 CAPLUS
- (32) Dellaria; US 6545017 B1 2003 CAPLUS
- (33) Gerster; US 4689338 A 1987 CAPLUS
- (34) Gerster; US 4698348 A 1987 CAPLUS
- (35) Gerster; US 4929624 A 1990 CAPLUS
- (36) Gerster; US 5037986 A 1991 CAPLUS
- (37) Gerster; US 5175296 A 1992 CAPLUS
- (38) Gerster; US 5266575 A 1993 CAPLUS
- (39) Gerster; US 5346905 A 1994 CAPLUS
- (40) Gerster; US 5367076 A 1994 CAPLUS
- (41) Gerster; US 5389640 A 1995 CAPLUS
- (42) Gerster; US 5741908 A 1998 CAPLUS
- (43) Gerster; US 5756747 A 1998 CAPLUS
- (44) Gerster; US 6110929 A 2000 CAPLUS
- (45) Gerster; US 6194425 B1 2001 CAPLUS
- (46) Gester; US 5268376 A 1993 CAPLUS
- (47) Hedenstrom; US 20020058674 A1 2002 CAPLUS
- (48) Jain; J Med Chem 1968, V11, P87 CAPLUS
- (49) Lindstrom; US 5446153 A 1995 CAPLUS
- (50) Lindstrom; US 5482936 A 1996 CAPLUS
- (51) Lindstrom; US 5693811 A 1997 CAPLUS
- (52) Littell; US 3314941 A 1967 CAPLUS
- (53) Miller; US 6083505 A 2000 CAPLUS
- (54) Nanba; US 6069149 A 2000 CAPLUS
- (55) Nikolaidis; US 5352784 A 1994 CAPLUS
- (56) Nikolaidis; US 5395937 A 1995 CAPLUS
- (57) Rice; US 6376669 B1 2002 CAPLUS
- (58) Skwierczynski; US 6245776 B1 2001 CAPLUS
- (59) Smith; US 20020055517 A1 2002
- (60) Testerman; Journal of Leukocyte Biology 1995, V58, P365 CAPLUS
- (61) Tomai; US 6039969 A 2000
- (62) Wick; US 5238944 A 1993 CAPLUS
- (63) Wozniak; Journal of the Royal Netherlands Chemical Society 1983, V102, P511 CAPLUS

10734306

=> s l10 and ethoxymethyl

24478 ETHOXYMETHYL


L11 12 L10 AND ETHOXYMETHYL

=> d scan

L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN 1H-Imidazo[4,5-c]quinoline-1-propanamine, 4-amino-2-(ethoxymethyl)-
6,7,8,9-tetrahydro- (9CI)

MF C16 H25 N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):11

L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-
c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI)

MF C18 H25 N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN 2-Thiophenesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-
c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI)


MF C21 H25 N5 O3 S2 . C2 H F3 O2

CM 1


10734306



CM 2




L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Carbamic acid, [2-[2-(ethoxymethyl)-5-oxido-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]-, 1,1-dimethylethyl ester (9CI).
 MF C22 H30 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Sulfamide, N'-[4-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-N,N-dimethyl-, mono(trifluoroacetate) (9CI)
 MF C19 H28 N6 O3 S . C2 H F3 O2

CM 1




10734306

CM 2




L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)-
α,α-dimethyl- (9CI)
MF C17 H23 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Methanesulfonamide, N-[3-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro-
1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI)
MF C17 H27 N5 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-
c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI)
MF C18 H25 N5 O3 S . C2 H F3 O2

CM 1


10734306



CM 2



L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Carbamic acid, [2-[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-
1,1-dimethylethyl]-, 1,1-dimethylethyl ester (9CI)
MF C22 H30 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 1-Naphthalenesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-1H-
imidazo[4,5-c]quinolin-1-yl]butyl]-5-(dimethylamino)-,
mono(trifluoroacetate) (9CI)
MF C29 H34 N6 O3 S . C2 H F3 O2

CM 1


10734306



CM 2



L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Carbamic acid, [2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]-, 1,1-dimethylethyl ester (9CI)
 MF C22 H31 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Methanesulfonamide, N-[3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI)
 MF C17 H23 N5 O3 S

10734306

